AC Immune’s ACI-35.030 selected for further development

AC Immune (ACIU) announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau vaccine candidate, has been selected for further development. The ACI-35.030 anti-pTau vaccine candidate is being developed in collaboration with Janssen Pharmaceuticals, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments species, both of which are closely implicated in Alzheimer’s disease. The excellent performance of ACI-35.030 in the trial participants potentially opens promising avenues for AD treatment and prevention, which could offer an important societal impact. We thank the team at Janssen for their contributions of valuable knowledge, expertise, and resources to support this collaboration." The selection of ACI-35.030 is supported by new clinical data from the Phase 1b/2a trial presented at the Clinical Trials on Alzheimer’s Disease Conference 2022. The vaccine candidate was generally well tolerated.